Drug Type AAV based gene therapy |
Synonyms adeno-associated virus 8 vector expressing functional human cDNA encoding the N-acetylgalactosamine-6-sulfate sulfatase |
Target |
Mechanism GALNS replacements(galactosamine (N-acetyl)-6-sulfatase replacements) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Mucopolysaccharidosis IV | Preclinical | US | 20 Sep 2024 | |
Mucopolysaccharidosis IV | Preclinical | US | 20 Sep 2024 |